Programme SOM0044 for Parkinson’s Disease
SOM0044 is a small molecule for the treatment of Parkinson’s disease.
Covid-19: Sensorion delays Phase ll trial due to slow recruitment rate
SENS-401 is a drug candidate intended for the protection of inner ear tissue from damages that can lead to progressive or sequelar hearing impairment. Credit: Travis Isaacs.
Learn more
Hover over the logos to learn more about the companies who made this project possible.
Close
-
Malvern Panalytical
Malvern Panalytical offers characterisation tools for molecular analysis and small...
About
Malvern Panalytical offers characterisation tools for molecular analysis and small drug discovery to help accelerate development for the pharmaceutical industry.
FollowMake an Enquiry
-
Jeeva Informatics Solutions
Jeeva Informatics Solutions (Jeeva) is a seed-stage start-up on a...
About
Jeeva Informatics Solutions (Jeeva) is a seed-stage start-up on a mission to develop artificial intelligence (AI)-driven decentralised clinical trials and optimise patient-focused clinical research.
FollowMake an Enquiry
-
SOM Biotech
SOM Biotech is an Artificial Intelligence AI drug discovery and...
About
SOM Biotech is an Artificial Intelligence AI drug discovery and development company focused on the development of therapies for orphan indications through the proprietary AI-based drug discovery technology.
FollowMake an Enquiry